Shanghai Shyndec Pharmaceutical's subsidiary obtained drug registration certificates for two products.

Shanghai Shyndec Pharmaceutical (600420.SH) announced that its holding subsidiary, China Pharmaceutical Group Zhijun (Shenzhen) Pharmaceutical Co., Ltd. (hereinafter referred to as Zhijun), and its wholly-owned subsidiary China Pharmaceutical Group Rongsheng Pharmaceutical Co., Ltd. (hereinafter referred to as Rongsheng) have recently received the "Drug Registration Certificate" issued by the National Medical Products Administration. The products involved are "Oseltamivir Phosphate Granules Suspension" and "Argatroban Injection". This time, Zhijun and Rongsheng obtained the above drug registration certificates and are considered to have passed consistency evaluation. This enriches the company's portfolio of antiviral, hematological, and hematopoietic system preparations, and enhances the company's comprehensive market competitiveness in the relevant drug areas, bringing positive impacts to the company's future development.